Company Overview
About Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
Business Model & Competitive Advantage
Biogen's neuroscience-focused biopharma model addresses the enormous unmet medical need in brain diseases — Alzheimer's disease affects 7 million Americans (projected 13 million by 2050), multiple sclerosis affects 1 million Americans, and Friedreich's ataxia is a devastating progressive neurological disease with no prior approved treatments — where the complexity of the blood-brain barrier, the lengthy time course of neurodegenerative disease, and the difficulty of measuring cognitive decline in clinical trials creates the scientific barriers to entry that have discouraged many large pharma companies from sustained neurodegeneration R&D investment. Biogen's neuroscience expertise (30+ years of MS drug development, SPINRAZA's SMA breakthrough, and the LEQEMBI Alzheimer's program) builds organizational capabilities — brain disease patient registries, FDA neurology division relationships, specialty neurology prescriber network — that are not replicable through acquisition alone. LEQEMBI's amyloid-clearing mechanism (humanized antibody targeting soluble amyloid beta protofibrils) represents the culmination of the amyloid hypothesis for Alzheimer's treatment that the industry has pursued for 20+ years.
Competitive Landscape 2025–2026
In 2025, Biogen competes in Alzheimer's disease therapeutics, multiple sclerosis, and rare neurological diseases against Eli Lilly (NYSE: LLY, donanemab/Kisunla Alzheimer's treatment competing directly with LEQEMBI), Novartis (NYSE: NVS, MS treatments including ofatumumab/Kesimpta), and Roche/Genentech (SIX: ROG, MS treatments ocrelizumab/Ocrevus and fenebrutinib) for Alzheimer's treatment market share and multiple sclerosis franchise resilience. LEQEMBI's primary competition comes from Eli Lilly's donanemab (Kisunla), which received FDA approval in July 2024 and demonstrated comparable efficacy with potentially more convenient dosing in its TRAILBLAZER-ALZ 2 clinical trial — creating a two-drug Alzheimer's market where Biogen/Eisai and Eli Lilly compete for neurologist prescribing and Medicare coverage. The 2025 strategy focuses on expanding LEQEMBI's commercial infrastructure (infusion center network, PET scan reimbursement for amyloid diagnosis, primary care physician education), accelerating SKYCLARYS into multiple countries beyond the US and Europe, and identifying pipeline assets to replace MS revenue decline through bolt-on acquisitions in neurology.
The Biogen Story
Founders
Company Timeline
Major milestones in Biogen's journey
Leadership Team
Meet the leaders behind Biogen
Christopher A. Viehbacher
Christopher A. Viehbacher joined Biogen as President, CEO, and Board member in November 2022. He previously served as global CEO of Sanofi for six years, overseeing significant portfolio transformation including the Dupixent partnership with Regeneron and the Genzyme acquisition. After 20 years at GlaxoSmithKline and his tenure at Sanofi, he co-founded Gurnet Point Capital, a Cambridge-based healthcare investment fund. Viehbacher has led Biogen's strategic transformation, balancing the company's foundational neuroscience focus with expansion into immunology and rare diseases.
Michael McDonnell
Mike McDonnell served as Executive Vice President and CFO from August 2020 to February 2025. He brought over 38 years of financial and accounting experience, including serving as CFO of IQVIA Holdings (2015-2020), Intelsat (2008-2015), and MCG Capital Corporation (2004-2008). McDonnell spent 14 years at PricewaterhouseCoopers, including 4 years as partner. He holds BS and MBA degrees from Villanova University and is a certified public accountant.
Priya Singhal, M.D., M.P.H.
Dr. Priya Singhal serves as Executive Vice President and Head of Development, promoted to this role in January 2023. She also served as interim Chief Medical Officer in 2024. Dr. Singhal leads Biogen's clinical development strategy, focusing on reviewing the existing pipeline with an eye toward improving its risk profile while advancing key candidates in neuroscience and rare diseases.
Alisha A. Alaimo
Alisha Alaimo serves as President and Head of North America, responsible for commercial operations in the United States and Canada. She is also a Board Member of the Biogen Foundation. Alaimo leads Biogen's business during what she describes as 'a really unique period in Biogen's history with multiple first-in-class drug launches in the U.S.,' including LEQEMBI for Alzheimer's and SKYCLARYS for Friedreich's ataxia.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Biogen is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $9700M in revenue, Biogen operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
YouShift
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Dusty Robotics
Dusty Robotics is a Mountain View, California-based construction robotics company — backed with $69.5 million in total funding from Root Ventures, Scale Venture Partners, Canaan Partners, GRIDS Capita
Compare Biogen with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Biogen? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Biogen Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Biogen vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →